The CLINUVEL Pharmaceuticals Limited (ASX: CUV) share price is sinking lower on Wednesday following the release of its half year results.
The biopharmaceutical company’s shares are currently down 7% to $21.58.
How did CLINUVEL perform in the first half?
For the six months ended December 31, CLINUVEL delivered an 11% increase in total revenue to $9.97 million. A key driver of this growth was the sales of its SCENESSE product in the European market.
SCENESSE is used for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria. Late last year the product finally received approval by the U.S. FDA.
In light of this approval, the company has invested heavily in key areas of the business to support its growing activities. This led to a sizeable 54% increase in expenses compared to the prior corresponding period. Which ultimately led to CLINUVEL reporting a 74% decline in net profit after tax to $1.06 million.
At the end of the period the company had cash of $57.4 million and no debt on its balance sheet.
CLINUVEL’s chief financial officer, Darren Keamy, was pleased with the company’s performance in the first half.
He said: “The eighth consecutive half year profit is a timed and well-managed outcome as it has been sustained in a period where the Group further re-invested in the business which, as expected, had an effect on the net profit result. We had long planned to establish cash reserves to accommodate for any economic downturns, allowing CLINUVEL to execute its plans without significant concerns about building a promising business.”
“As part of our long-term plans, growth in the existing revenue base from distribution of SCENESSE in the Eurozone has enabled the Group to self-finance its growth which include expansion into the US. In balancing the entry into new territories, diffusion in new medical indications and control over our costs, we continue to progress the strategic initiatives set by the Board for long term performance of the Group,” he added.
No guidance was provided for the second half.
These 3 stocks could be the next big movers in 2020
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
*Returns as of 6/8/2020
No tickers found. You need to add tickers and save as draft before fetching disclosure
- Why I would buy CBA (ASX:CBA) and this beaten down ASX share – September 22, 2020 4:31pm
- 3 quality small cap ASX shares with very strong growth potential – September 22, 2020 4:30pm
- Buy these ASX dividend shares to beat low interest rates – September 22, 2020 4:00pm